Key Points
- SiBone CEO Laura Francis sold 51,884 shares at an average price of $19.46, generating approximately $1.01 million; she retained 321,386 shares after the transaction. She also sold an additional 3,923 shares the following day for about $78,538.
- SiBone’s latest quarterly results exceeded expectations, with a loss of $0.09 per share versus the $0.15 consensus estimate and revenue of $56.01 million compared with estimates of $55.34 million.
- Analysts remain generally positive, with six Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $24.17. Institutional investors own approximately 98.11% of the company.
SiBone (NASDAQ:SIBN - Get Free Report) CEO Laura Francis sold 3,923 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $20.02, for a total value of $78,538.46. Following the completion of the sale, the chief executive officer directly owned 317,463 shares of the company's stock, valued at approximately $6,355,609.26. This represents a 1.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Laura Francis also recently made the following trade(s):
- On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.
SiBone Stock Performance
NASDAQ SIBN opened at $19.96 on Friday. The stock's fifty day moving average is $17.49 and its two-hundred day moving average is $15.33. The firm has a market capitalization of $885.23 million, a P/E ratio of -58.71 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89.
SiBone (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The company had revenue of $56.01 million during the quarter, compared to analysts' expectations of $55.34 million. On average, research analysts anticipate that SiBone will post -0.4 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the stock. UBS Group upped their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Truist Financial reaffirmed a "buy" rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. TD Cowen boosted their target price on shares of SiBone from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Finally, Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.17.
View Our Latest Research Report on SiBone
Institutional Investors Weigh In On SiBone
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd purchased a new stake in SiBone in the fourth quarter valued at $29,000. Versant Capital Management Inc grew its holdings in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock worth $29,000 after purchasing an additional 887 shares during the period. Royal Bank of Canada grew its holdings in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company's stock worth $29,000 after purchasing an additional 736 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company's stock worth $38,000 after purchasing an additional 1,941 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of SiBone during the 4th quarter worth about $53,000. Institutional investors and hedge funds own 98.11% of the company's stock.
SiBone Company Profile
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
